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Abstract 
 
This thesis describes an in-vivo evaluation of ethanolic extracts of 
Astragalus membranaceus and fractions derived from this extract 
administered either orally by gavage or by intraperitoneal injection to 
Balb/c mice. Total antibody titre was used as an indicator of humoral 
immune response. Cell mediated immune response was determined using 
Interferon-γ and Interleukin-12 as indicators. Additionally, mice were 
vaccinated with a killed Salmonella typhimurium vaccine, previously 
demonstrated to induce humoral response but not cell mediated 
immunity, to determine whether the acquired immune response was 
enhanced or suppressed. Serum was analysed for total antibody titre using 
an enzyme-linked immunosorbent assay. Serum and splenocyte culture 
supernatants were analysed for levels of interferon-γ and interleukin-12. 
No statistically significant differences were observed between groups 
either orally gavaged or intraperitoneally injected with extracts of 
Astragalus membranaceus, or orally gavaged with fractions derived from 
this extract when compared with the control groups.  
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Chapter 1: Introduction 
 
Astragalus membranaceus has been used in Traditional Chinese Medicine 
(TCM) for conditions such as diarrhoea, fatigue and loss of appetite as 
well as a tonic for conditions of depleted qi. Western herbal applications 
of this herb have been predominantly as an immune response potentiator. 
However, little experimental evidence to support the therapeutic claims 
has been published. In this study, the immunomodulatory potential of 
ethanolic extracts of the root of Astragalus membranaceus was 
investigated. 
 
Select previous studies have claimed that Astragalus membranaceus may 
potentiate immune responses (Yoshida et al, 1997). although these studies 
have involved administration of Astragalus membranaceus  extracts via 
an intraperitoneal injection. This is at odds with the accepted use of this 
traditional Chinese medicine for modulating the immune response where 
the extracts of this herb are administered by exclusively the oral route. 
Furthermore, these products are in general ethanolic extracts rather than 
the aqueous preparations reported in a number of previous investigations 
(Rittenhouse et al, 1991; Sun et al, 1983) 
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The aim of this investigation was to determine whether oral 
administration of ethanolic extracts of the roots of Astragalus 
membranaceus promoted antibody response  and/ or induced cell 
mediated immunity (CMI) in mice vaccinated with killed cell Salmonella 
typhimurium vaccine. This vaccine has been reported to induce only 
antibody response but no CMI (Harrison, 1997; Mukkur et al, 1991; 
Mukkur et al, 1997). Antibody responses were measured using an enzyme 
linked immunosorbent assay whereas cell mediated immunity was 
measured using interferon-gamma (IFN-γ) as an indirect indicator of the 
cellular arm of the immune response and interleukin-12 (IL-12) as an 
indicator of innate immunity. 
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Chapter 2: Literature Review 
 
2.1 Astragalus membranaceus 
2.1.1 Botanical Aspects. 
The genus Astragalus contains more than 2000 species distributed 
worldwide and is a member of the Leguminosae family. Astragalus 
membranaceus is commonly referred to as the membranous milk-vetch 
(English), huang qi (Chinese), ogi (Japanese) and hwanggi (Korean).  
 
2.1.2 Traditional Use. 
Used in Traditional Chinese medicine (TCM), Astragalus membranaceus 
(hereafter referred to as Astragalus) is identified as a herb which tonifies 
the qi and is indicated in conditions of spleen qi deficiency such as 
diarrhoea, fatigue and loss of appetite. It is also stated to raise the yang qi 
of the spleen and stomach and address prolapse of organs such as the 
uterus, stomach and anus, as well as assisting in control of uterine 
bleeding. Astragalus has been stated to tonify the lung qi and is therefore 
used in cases of colds, spontaneous sweating and shortness of breath. 
Other traditional uses have included wasting disorders, night sweats, 
chronic ulceration and sores, numbness and paralysis of the limbs and 
oedema (from deficiency). The part of Astragalus traditionally used is the 
root, with only one investigation found during the course of this study of 
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the use of the aerial parts of the plant (Yan et al, 1999). It is classically 
prescribed in TCM in combination with other Chinese medicinal herbs as 
a dried root, powdered or as a decoction, with the combination depending 
on the desired therapeutic effect and the specific TCM diagnosis.  
 
2.1.3 Chemistry 
Principle constituents of Astragalus membranaceus stated in published 
literature include polysaccharides, saponins, flavonoids, amino acids and 
various trace elements. Levels of Astragalosides, a cycloartane triterpene 
glycoside, are often used as indicators of herb quality. The astragalosides 
are a series denoted as I- VII based on a aglycone cycloastragenol and 
containing from one to three sugars attached at the 3-,6- and 25- 
positions. In astragalosides I-III the 3- glucose is acetylated. 
(Anonymous, Alternative Medicine Review, 2003)  
 
Hairy root cultures were used to isolate Agroastragaloside II, a new 
astragaloside, structure of this was established as 3-O-β-(2’-O-acetyl)-D-
xylopyranosyl-6-O-β-D-glucopyranosyl-(24S)-β,6α,16β,24,25-
pentahydroxy-9,19-cyclolanostane. The previously reported 
astragalosides, namely astragaloside II, isoastragaloside I and 3-O-β-D-
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xylopyranosyl-cycloastragenol were also isolated from the culture of 
hairy roots (Hirotani et al. 1994). 
 
2.1.4 Hepatoprotective effects of Astragalus membranaceus 
Administration of an ethanolic extract of astragalus root has been 
reported to alleviate liver damage induced by the administration of 
stilbenemidine. It was reported that pre-administration of astragalus 
extract to mice reduced elevated serum glutamic-pyruvic transaminase 
levels and subacute toxicity of stilbenemidine exposure, decrease 
pentobarbital induced loss of righting reflex and protected hepatic cells 
from pathological changes (Zhang et al. 1990). 
 
2.1.5 In vitro immunological studies of Astragalus membranaceus  
Studies utilising human melanoma cell lines A375P and HS294T 
demonstrated that concomitant addition of Astragalus membranaceus 
extract with IL-2 to cell cultures showed a ten-fold potentiation in IL-2 
activity manifested by tumour cell killing activity. A significant reduction 
in the number of effector LAK cells following LAK cell generation with 
Astragalus membranaceus, fractionated on a Sephadex Sephacryl S-200 
column and retaining the fraction with an estimated molecular weight of 
20000 – 25000, plus IL-2 were required for equicytotoxic reaction, when 
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compared to the addition of IL-2 without the Astragalus fraction in 
isolation was observed (Chu et al, 1988). 
 
Tumour cells are known to produce substances which suppress the 
function of macrophages (Israel et al, 1981). Macrophage suppression by 
urological tumour lines was demonstrated to be reversed in-vitro by the 
addition of aqueous extracts of Astragalus membranaceus or Ligustrum 
lucidum (Rittenhouse et al, 1991). 
 
Aqueous extracts of Astragalus membranaceus were evaluated using the 
local xenogenic graft-versus-host reaction. This study utilised the crude 
extract (designated Fraction 7) in addition to a number of purified 
fractions. Greater immunomodulating response characterised by local 
xenogenic graft-versus-host reaction from two of the fractions examined 
(fractions 3 and 8) were observed than that exhibited by the precursor 
crude extract (Chu et al, 1988). 
 
Yoshida et al (1997) studied the immunomodulating potential of a variety 
of chinese medicinal herbs by assessing the ability of the extracts to 
stimulate the proliferation of murine spleen cells and reported that 
extracts of Astragalus membranaceus and Oldenlandia diffusa in 
particular promoted the proliferation of murine spleen cells. 
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 2.1.6 In-vivo immunological studies on Astragalus membranaceus 
 
Chu et al (1988) injected fraction F3 intravenously into rats whose 
immune response had been suppressed by administration of 
cyclophosphamide. Administration of the F3 fraction was found to 
markedly enhance the ability of rats to reject the xenogenic graft and was 
therefore taken as a strong indicator of the extract’s immune potentiating 
activity in vivo (Chu et al, 1988). 
 
Zhao et al (1990) administered Astragalus membranaceus extracts, 
prepared according to the methods of Chu et al (1988), by intraperitoneal 
injection to both normal mice or mice immunosuppressed by 
cyclophosphamide or radiation or by ageing. The authors reported an 
enhanced antibody response to a trinitrophenol–horse red blood cell 
antigen,  a T-dependant antigen that was associated with an increase in T-
helper cell activity in both the normal and immunosuppressed mice. 
Further, it was reported that the observed immunomodulatory activity of 
the extracts was associated with the carbohydrate content of the extract. 
 
Ying-Zhen et al (1990) injected a refined aqueous extract, prepared by 
precipitation in alcohol of Astragalus membranaceus, intraperitoneally to 
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determine its effect on experimentally-induced coxsackie B-3 viral 
myocarditis in 4 week old male Balb/c mice. Examination showed that 
the mice treated with extract exhibited lesser severity and reduced area 
displaying myocardial lesions. Virus titre was also reduced in the treated 
group.  
 
The effect of Astragalus extracts on inhibition of tumour cells has also 
been studied in-vivo  (Lau et al, 1994). Balb/c mice were transplanted 
intraperitoneally with renal adenocarcinoma cell line (Renca). The 
treatment group was then injected with an aqueous extract of Astragalus 
membranaceus and Ligustrum lucidum by the intraperitoneal route for 10 
days. Survival was enhanced with administration of the extract with a 
cure rate of 57% when the tumour load was 2x 105 and 100% when the 
tumour load was 1x 105 when compared with the control mice 
administered saline. Splenocytes from mice transplanted with the Renca 
cell line were also shown to have a depressed capability for responding to 
IL-2 in generating lymphokine-activated killer cells (LAK cells). It was 
suggested that the anti-tumor activity of the extract may be a result of 
augmentation of the phagocyte and LAK cell activity  
 
Khoo and Ang (1995) fed Wistar rats with cyclophosphamide-induced 
myelosupression a dose of 240mg of a suspension of a commercially 
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available dried extract of Astragalus membranaceus or Ligustrum 
lucidum. Daily neutrophil count and platelet count levels were monitored. 
No differences were observed between the study and control groups 
(Khoo and Ang, 1995). In contrast, Yan et al (1999) evaluated an extract 
of the stems and leaves of Astragalus membranaceus for 
immunomodulatory potential and showed the extract to promote the 
proliferation of lymphocytes, raise the T-cell count and elevate LAK 
activity induced by IL-2 in mice. 
 
Hairy roots of Astragalus membranaceus were produced using a large-
scale culture technique. These cultured roots were assessed to have a 
similar quality to traditionally produced roots with respect to levels of 
polysaccharides, saponins and astragalosides. Aqueous extracts of the 
cultured hairy root was dosed orally into cyclophosphamide suppressed 
rats and determined the immune response by assessment of spleen 
weight, thymus weight, carbon clearance, transformation of lymphatic 
cells and hemolysin antibody formation. Immune response triggered by 
the cultured material was reported as similar to those observed with root 
material, using  spleen weight, thymus weight, clearance of carbon 
particles, transformation of lymphatic cells and hemolysin antibody 
formation as indicators (Zhiren et al, 1998). 
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 2.2 Whole-cell formalin-killed Salmonella typhimurium vaccine 
It was decided to use killed S. typhimurium vaccine that has been reported 
to induce only antibody response and cell mediated immunity in mice to 
determine whether oral administration of A. membranaceus extracts or 
fractions could induce a cell mediated immunity or immune response 
(CMI). The choice of this antigen system is also significant since humoral 
immunity mediated by antibodies does not protect mice against challenge 
with virulent Salmonella species, whereas a live attenuated Salmonella 
species that induce production of antibodies and CMI are highly effective 
in protecting mice against salmonellosis. (Mukkur et al. 1991, Mukkur et 
al. 1997) 
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Chapter 3: Materials and Methods 
 
3.1 Herbs 
 
The Astragalus membranaceus root material was obtained from 
Greenridge Botanicals, A Division of Thursday Plantation Laboratories 
Ltd (Ballina, NSW). The herb was sourced from crops grown at the 
Greenridge farm located at Lobwein’s Rd, Kingsthorpe Queensland. 
Following harvest, the roots were hot air dried at 70°C and stored as 
coarsely cut sections. All herb used in these studies was randomly drawn 
from commercially harvested stocks. 
 
3.2 Preparation of Herbal Extracts 
 
3.2.1 Confirmation of authenticity 
 
Confirmation of authenticity of the herbal starting material used in these 
studies was accomplished by the use of thin-layer chromatography 
(Appendix A: Thin Layer Chromatography method) Additionally, 
observation of the crop prior to harvest was consistent with published 
descriptions of the growth habits of Astragalus membranaceus. The plant 
is a perennial herb 25-40cm high. Leaves are oblong and 3-6 cm long, 
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petiole obsolete, stipules free, cauline, green, triangular ovate, sparingly 
vested on the outside with white hair. Leaflets oblong-ovate, oval or 
oblong-oval (World Health Organisation, 1999). 
 
3.2.2 Preparation of Astragalus membranaceus Extract 
 
The extraction process employed in this study was selected to be 
equivalent to that utilised by Greenridge Botanicals, a Division of 
Thursday Plantation Laboratories Ltd., in the preparation of commercial 
extracts of Astragalus membranaceus. 
  
Dried Astragalus membranaceus roots were hammer milled to a coarse 
powder. Two hundred grams of the milled herb was macerated in eight 
hundred millilitres of 60% v/v ethanol-water for seven days in a glass 
vessel. Following maceration, the supernatant was decanted off and the 
residual wetted herb mass was pressed in a hand operated garlic press to 
maximise recovery of the applied extraction solvent. A total of five 
hundred and sixty millilitres of solvent was recovered. The volume of the 
recovered liquid was reduced to 143.6mL using a rotary evaporator. The 
concentrated liquid was diluted to 200mL using 14.3mL distilled water 
and 42.1mL of ethanol (95%). The resultant extract was thus a 1:1 extract 
(1mL of the final liquid being equivalent to 1g of dried herb) prepared at 
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a final ethanol content of 20% v/v. This extract is equivalent to that used 
by Greenridge Botanicals, a Division of Thursday Plantation Laboratories 
Ltd in the product AstraForte, a blend of extracts of Astragalus 
membranaceus, Ganoderma lucidum and Ligustrum lucidum. Extracts 
were filter sterilised by passing through a 0.45 micron membrane filter 
prior to administration. 
 
3.3 Separation of herbal fractions 
 
Preparation of fractions of components of Astragalus extract was carried 
out to allow identification of the fractions containing the 
immunostimulatory or immunoinhibitory actions of compounds present 
in the herb.  
 
100mL of the whole extract prepared as described in Section 3.2 was 
placed into a 250mL separating funnel. To this was added 50ml of n-
hexane. The flask was agitated and the phases allowed to separate. The 
aqueous phase was drained from the separating funnel and the organic 
phase collected. This process was repeated a further two times and the 
organic phases combined. The 150mL of hexane was then rotary 
evaporated to dryness and the residue suspended in 100mL of 20% v/v 
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ethanol by sonication. This liquid represented the lipophilic compounds 
fraction. 
 
An aliquot of 20mL of the aqueous phase from the above described 
procedure was chilled to 4°C and 200mL of ethanol (95% v/v) chilled to 
4°C was added. The combined liquids were mixed thoroughly and 
allowed to stand in a bath of iced water for ten minutes. The liquid was 
then filtered through a Whatman No 4 filter paper and the collected 
residue washed with three lots of 10mL of 95% ethanol chilled to 4°C. 
The collected residue was washed from the filter followed by sonication 
in 20mL of 20% v/v ethanol: water. This was considered to represent the 
hydrophilic polysaccharide fraction of the herb and is referred to as the 
polysaccharide fraction in the text. 
 
The filtrate from the above procedure was retained and rotary evaporated 
to dryness. The residues obtained were suspended in 20mL of 20% v/v 
ethanol by sonication. This fraction was referred to as the hydrophilic 
fraction that represented the non-polysaccharide water soluble 
components of the whole Astragalus extract. 
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 3.4 Animals 
 
Mice used to conduct these studies were sourced from the Animal 
Resource Centre, Perth WA. Six week old female, specific pathogen-free 
Balb/c mice were allowed to acclimatise for one week prior to being 
separated into groups of 10 mice each for the conduct of the studies. All 
mice were housed 10 per cage in the general housing area of the animal 
house at the University of Southern Queensland. Mice received unlimited 
water and mouse/rat chow. The temperature was maintained at a constant 
22°C and a 12 hours light/ 12 hours dark cycle was in operation 
throughout the duration of the studies. All experiments carried out in this 
investigation were approved by the USQ Animal Ethics Committee. 
 
3.5 Bacterial Strains 
 
Salmonella typhimurium aroA (CS322) was used from stocks held by the 
Department of Biological and Physical Sciences, University of Southern 
Queensland. The cultures used had been stored at -70°C. Subculturing 
onto Miller’s Luria-Bertani (LB) agar and growth in Miller’s Luria-
Bertani (LB) broth was accomplished as required. 
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 3.6    Preparation of vaccines  
  
Ten microlitres of the stock culture of Salmonella typhimurium was 
streaked onto Miller’s LB agar and incubated overnight to obtain isolated 
colonies. A single colony was inoculated into 200mL of Miller’s LB 
broth and incubated at 37°C for 18 hours with agitation at 150 rpm in a 
Bioline Shaker Incubator (Edwards Instrument Co., Australia). A series 
of dilutions over a range from 10-4 to 10-8 were prepared in LB broth and 
plated on LB agar and incubated overnight at 37°C in order to determine 
the number of colony forming units per mL in the culture. Formalin was 
added to the broth at a final concentration of 1% and the broth further 
incubated at 37°C for 4 hours with agitation at 150 rpm. An aliquot of 
100 microlitres of the broth was then streaked on Miller’s LB agar and 
incubated at 37°C overnight as a check for sterility. The broth culture was 
centrifuged at 7000 rpm for twenty minutes at ambient temperature. The 
supernatant was discarded and the pellet washed twice with sterile 
phosphate buffered saline. The final pellet was then suspended in 50mL 
of phosphate buffered saline and stored under refrigeration at 4°C prior to 
use. 
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 3.7 Preparation of whole-cell aroA Salmonella typhimurim (CS322) 
antigen 
 
Salmonella typhimurium strain CS322 aroA was prepared as described in 
Section 3.5. The final pellet was suspended in filter sterile coating buffer 
and adjusted to an optical density of 0.4 at 610nm. This antigen was 
stored refrigerated at 4°C prior to use. 
 
3.7.1 Preparation of Salmonella typhimurium lysate for splenocyte 
stimulation. 
 
Lysate of Salmonella typhimurium was prepared according to a 
modification of the procedure detailed by Villarreal (1992). Salmonella 
typhimurium was grown on motility test agar overnight at 37°C. Bacteria 
with the highest motility was then inoculated into 400mL of tryptic soy 
broth and incubated overnight at 37°C. The broth was then centrifuged at 
13000 x g for 10 minutes and the supernatant discarded. The pellet was 
then washed with phosphate buffered saline containing 5mM EDTA, 
centrifuged and re-washed. The pellet was then resuspended in 1/150 of 
the original volume and the cells disrupted by three 2 minute bursts of 
17 
sonication (60 duty cycle,output 7). Disruption of cells was confirmed by 
gram stain. The resultant lysate solution was then diluted to 1/3 of the 
original volume in sterile PBS and centrifuged at 13000 x g for 10 
minutes to remove insoluble matter. The supernatant was passed through 
a 0.2 μ syringe filter and placed in a sterile tube for storage at 4°C. The 
protein concentration was determined using a Coomassie® Plus Protein 
Assay Reagent Kit. 
 
3.8 Procedure for collection of samples from mice and anaesthesia 
of mice 
 
3.8.1 Serum Samples: 
 
On the final day of each experiment, serum was collected as follows. 
Mice were anaethesised with a mixture of 40 microlitres of ketamine 
(100mg/mL) and 40 microlites of xylazine (20mg/mL). Blood samples 
were obtained by cardiac puncture using a 23G ¾” needle. (Becton-
Dickinson, Eight Mile Plains, Qld). Collected blood was placed in a 
1.5mL microfuge tube and immediately capped. Immediately following 
collection of the blood sample, cervical cordotomy was performed on the 
mice to ensure a rapid and painless euthanasia. 
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The collected blood sample was allowed to clot for 15 minutes and then 
centrifuged at 3000xg for five minutes (Mikro 12-24 centrifuge, Hettich 
Zentrifugen, Tuttlingen). The supernatant serum was removed using a 
glass pastuer pipette and stored at -20°C prior to analysis.  
 
3.8.2 Collection of spleens for preparation of splenocyte 
supernatants 
Spleens were excised from five of the mice cadavers in different groups 
and placed in 10mL of tissue culture media and splenocyte culture 
supernatants prepared as described below. 
 
3.8.3 Preparation of Splenocyte culture supernatants 
 
Immediately following collection of the blood samples by cardiac 
puncture as described, the spleen was dissected from five mice per group. 
These spleens were placed into tissue culture media (refer Appendix B). 
The collected spleens were held for no longer than fifteen minutes prior 
to proceeding with the culture preparation. The spleens and tissue culture 
media were then poured into a sterile cell strainer (Becton-Dickinson, 
Eight Mile Plains Qld) on top of a sterile 50mL tube. The cells were 
mashed through the grid of the strainer using the plunger from a sterile 
1mL syringe (Becton-Dickinson, Eight Mile Plains Qld). Two washes of 
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approximately 5mL of tissue culture media was used to wash the cells 
through the strainer. The cells were then pelleted by centrifuging for 10 
minutes at 1000rpm at ambient temperature. The supernatant was then 
decanted and the cell pellet was washed with 10mL of tissue culture 
media. The cell pellet was washed again with 10mL of tissue culture 
media and centrifuged for 10 minutes at 1000rpm and ambient 
temperature. The final cell pellet was then suspended into 10mL of the 
tissue culture media. An aliquot of 10μL of the cell suspension was added 
to 90μL of the tissue culture media and mixed thoroughly. 10μL of this 
was added to 10μL of tryptan blue and mixed thoroughly. A volume of 
10μL of this was transferred to a haemocytometer and the white blood 
cells were counted. The concentration of cells was then adjusted to          
5 x 106 cells per mL and 2mL of this suspension was dispensed into 9 
wells of a 24 well culture plate (TPP, Switzerland). 100μL of Salmonella 
typhimurium lysate (refer 3.10) which was equivalent to approximately 
2μg of protein per millilitre was added to each well. The plate was then 
covered with a loose fitting lid and incubated at 37°C. Supernatant was 
recovered from wells at 72 hours. Collected supernatant was stored at -
20°C prior to analysis. Tissue culture procedures were conducted in a 
Class II Biological Safety Cabinet. 
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3.9 Estimation of antibody levels by enzyme-linked 
immunosorbent assay (ELISA) 
 
The method used was an indirect enzyme-linked immunosorbent assay 
(ELISA) as described elsewhere (Mukkur et al., 1995). One hundred 
microlitres of whole cell S. typhimurium antigen (refer 3.7.2) suspended 
in coating buffer (refer Appendix B) was dispensed into columns 2 – 10 
of a 96 well plate. The plate was then covered with a plastic film and 
incubated at 4°C overnight. Following this, 100μL of 0.2% gelatin in 
coating buffer was added to the wells in order to block the plate. 200μL 
of 0.2% gelatin in coating buffer was added to the wells in column 11 to 
act as the antigen control. The plate was covered with plastic film and 
incubated at 4°C overnight. Following this incubation the film was 
removed, the plate emptied, tapped dry on absorbent towelling and 
irrigated with wash buffer. The plate was allowed to stand for 3 minutes 
and the procedure repeated a further two more times. 
 
Serial dilutions of serum in phosphate buffered saline were prepared of 
each sample over a range from 1/100 to 1/12800. Following washing of 
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the plate, 100μL of the dilutions were added to the plates. The plate was 
incubated for one hour at 37°C covered with plastic film. 
 
Following this the plate was washed three times with wash buffer, 
allowing the wash buffer to stand for three minutes with each wash. 
100μL of the secondary antibody, represented by goat anti-mouse 
polyvalent immunoglobulins (Sigma, St Louis, Mo) was then added to the 
wells of column 2 to 11. Minimum titre quoted by the manufacturer for 
the secondary antibody was 1:10,000. 
 
The plate was washed three times with wash buffer again and Sigma-
Fast™(Sigma, St Louis, Mo) made up according to the manufacturer’s 
directions. 100μL was added to all wells of the plate used in the test. The 
plate was then covered with aluminium foil and incubated for 30 minutes. 
Absorbances for the contents of the wells was then read on a micro-plate 
reader (Bio-Rad Model 550, Hercules Ca) at 450nm. The antibody titre 
was then able to be established by plotting the absorbance value and 
corrected for non-specific binding  followed by extrapolation to establish 
the antibody titre. 
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3.10 Interleukin-12 determination by enzyme-linked 
immunosorbent assay (ELISA) 
 
Assay for interleukin-12 levels was conducted using Cytoscreen Mouse 
IL-12+p40 kit (Biosource International, Camarillo Ca). Analysis was 
carried out according to the manufacturer’s directions for use of the kit 
(Appendix C). Samples of serum (50μL) were aliquoted into the pre-
coated wells of the plate with the biotin conjugate. The plate was 
incubated for two hours at ambient temperature. Following this period of 
incubation, the plate was washed four times with wash buffer. 
Streptavidin-HRP was added and the plate incubated for 30 minutes at 
ambient temperature. The plate was then washed four times with the wash 
buffer. Colour substrate was added to each well and the plate incubated 
for 30 minutes. Stop solution was then added and the plate read in a 
micro-plate reader (Bio-Rad Model 550, Hercules Ca) at 450nm. IL-12 
levels were calculated using the generated standard curve.  
 
3.11 Determination of Interferon-γ (IFN-γ) levels by enzyme-linked 
immunosorbent assay (ELISA) 
Interferon-γ levels were determined using a Quantikine® Mouse IFN-γ 
test kit (R&D Systems Inc, Minneapolis MN). Analysis was conducted 
23 
according to the manufacturer’s directions for use of the kit (Appendix 
C). 50μL of splenocyte supernatant samples was aliquoted into the wells 
along with 50μL of the assay diluent. The plate was covered and 
incubated at ambient temperature for 2 hours. Following incubation the 
plate was washed five times with wash buffer. 100μL of conjugate was 
added to the wells, the plate covered and incubated at ambient 
temperature for 2 hours. The plate was washed five times with wash 
buffer. 100μL of substrate solution was added to each well and the plate 
incubated in the dark for 30 minutes at ambient temperature. 100μL of 
stop solution was added to each well and the plate read in a micro-plate 
reader (Bio-Rad Model 550, Hercules Ca) at 450nm. Interferon-γ levels 
in the samples were calculated using the generated standard curve.  
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3.12 Evaluation of Immunomodulatory Properties of the Crude 
Extract or Fractions Derived from Astragalus membranaceus 
 
3.12.1 Experimental design for determination of total antibody titre 
and Interferon-γ levels in mice administered Astragalus 
membranaceus via oral gavage   
  
For this study, forty female specific pathogen free Balb/c mice were 
randomly assigned into four groups of ten mice per cage. The assigned 
groups were treated as follows: 
 
Group1: Mice in this group were dosed daily with 1.71 microlitres per 
day of the extract of Astragalus membranaceus prepared as described in 
3.2.2. This is equivalent to 1.71mg of the dried root matter. The extract 
was suspended in phosphate buffered saline to a total volume of 250 
microlitres and administered orally using a flexible plastic gavage tube 
(the plastic sheath of a 24G ¾”, Insyte™ Catheter, Becton-Dickinson, 
Eight Mile Plains, Qld). Extract was administered for a period of 28 days. 
On the seventh day, mice were vaccinated with a single dose of whole 
cell killed Salmonella typhimurium vaccine (2.5 x 107 colony forming 
units). This vaccine was administered by a single intraperitoneal 
injection. On day 28 of the study, serum was collected as detailed. 
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Methods used for collection of serum samples and spleens from 
euthanased mice and preparation of splenocyte supernatants is  described 
in Sections 3.8.1, 3.8.2 and 3.8.3 
 
Group 2: Mice were dosed orally with 250 microlitres per day of sterile 
phosphate buffered saline. No vaccination was performed. Methods used 
for collection of serum samples and spleens from euthanased mice and 
preparation of splenocyte supernatants is  described in Sections 3.8.1, 
3.8.2 and 3.8.3. 
 
Group 3: Mice were dosed orally with 250 microlitres per day of sterile 
phosphate buffered saline. After seven days, the mice were vaccinated 
with a single dose of whole cell killed Salmonella typhimurium vaccine 
(2.5 x 107 colony forming units). This vaccine was administered by a 
single intraperitoneal injection. Methods used for collection of serum 
samples and spleens from euthanased mice and preparation of splenocyte 
supernatants is  described in Sections 3.8.1, 3.8.2 and 3.8.3. 
 
Group 4: Mice were dosed orally with 1.71 microlitres of extract 
suspended in phosphate buffered saline to a total volume of 250 
microlitres as described for group 1. Methods used for collection of 
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serum samples and spleens from euthanased mice and preparation of 
splenocyte supernatants is  described in Sections 3.8.1, 3.8.2 and 3.8.3. 
 
3.12.2 Experimental design for the determination of total 
antibody titre and interferon-γ levels in mice 
administered Astragalus membranaceus extract by the 
intraperitoneal route 
  
For this study, thirty female specific pathogen free Balb/c mice were 
randomly assigned into three groups of ten mice per cage. The assigned 
groups were treated as follows: 
 
Group 1. Mice were administered a single dose of 48 microlitres of 
Astragalus membranaceus 1:1 extract suspended to a total volume of 100 
microlitres in sterile phosphate buffered saline on day one of the study. 
On day twenty-eight, samples were collected as described in Sections 
3.8.1, 3.8.2 and 3.8.3. 
 
Group 2: Mice were administered a single dose of 48 microlitres of 
Astragalus membranaceus 1:1 extract suspended to a total volume of 100 
microlitres in sterile phosphate buffered saline on day one of the study. 
On the seventh day, mice were vaccinated with a single dose of whole 
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cell killed Salmonella typhimurium vaccine with an equivalent of 2.5 x 
107 colony forming units. This vaccine was administered by a single 
intraperitoneal injection. On day twenty-eight, samples were collected as 
described in Sections 3.8.1, 3.8.2 and 3.8.3. 
 
Group 3: Mice were administered a single dose of 100 microlitres  of 
sterile phosphate buffered saline by intraperitoneal injection on day one 
of the study. On the seventh day, mice were vaccinated with a single dose 
of whole cell killed Salmonella typhimurium vaccine at a level of 2.5 x 
107 colony forming units by the intraperitoneal route. On day twenty-
eight, samples were collected as described in Sections 3.8.1, 3.8.2 and 
3.8.3 
 
 
 
3.13 Statistical analysis  
All statistical analysis was conducted using Instat+ for Windows, version 
3.024. Non-parametric analysis of variance (ANOVA) was conducted for 
the purpose of group comparisons in all studies (Steel et al, 1980). 
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Chapter 4: Results 
 
4.1 Authentication of herbal material 
Herbal material used in the preparation of extracts was drawn from plants 
grown at the Greenridge Botanicals (Aust) Pty Ltd farm located at 
Lobweins Road Kingsthorpe Queensland, Australia. Inspection of the 
crop during the growing period revealed plants consistent with the 
published descriptions and photographs of Astragalus membranaceus 
(World Health Organisation, 1999).  
 
Root stock used in the preparation of extracts was subsequently drawn 
from commercial harvests of these plants. Macroscopic assessment of the 
harvested root material in comparison with a verified reference sample of 
Astragalus membranaceus showed no major differences. Thin layer 
chromatography of the dried plant matter was used to confirm 
authenticity of the herb (Figure 1). Comparison was made against 
botanically verified Astragalus membranaceus root (Howard Hollows, 
Adelaide, Australia). 
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Figure 4.1: Thin layer chromatography of Astragalus membranaceus.  
Lane 1 authenticated Astragalus membranaceus, lanes 2 and 3 harvested 
herb. (Silica C60 F264 plates, Solvent system CH3COOH: Formic Acid: 
H2O: Ethyl Acetate 11:11:27:100; Plate development spray 1% w/v 
methanolic diphenylboric acid followed by 5% ethanolic polyethylene 
glycol. Viewed under UV light 365nm. 
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Review of the TLC plates showed a high degree of consistency between 
the band patterns of the herb used in preparation of the extracts and the  
reference material. Two major bands were observed at approximately Rf 
0.8 and a further two at Rf 0.6, Single bands were observed at 0.25 and 
0.4.No visible differences were observed between the sample and the 
reference material. It was determined that the macroscopic identification 
and assessment of the thin layer chromatography provided sufficient 
confirmation of starting material identity to be satisfied that the prepared 
extracts were of Astragalus membranaceus.  
 
4.2 Imunomodulatory Properties of the Crude Extract or Fractions 
Derived from Astragalus membranaceus 
 
4.2.1 Total antibody titres in mice following oral gavage with 
Astragalus membranaceus  
In this study, four groups of mice were gavaged with  A. membranaceus 
extract by the oral route. Two groups were vaccinated with killed 
Salmonella typhimurium vaccine whereas the remaining groups were 
unvaccinated. Serum antibody titres at 28 days post-immunisation are 
shown in Figure 4.2. Statistical analysis for this study is presented in 
Appendix D.  
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Figure 4.2 Histogram of total antibody titres for oral administration of 
Astragalus membranaceus extract or placebo (Phosphate buffered saline) 
Legend: Ext – Astragalus membranaceus extract, PBS- phosphate 
buffered saline, PBS Vac – Phosphate buffered saline and vaccinated, Ext 
Vac- Astragalus membranaceus extract and vaccinated. 
 
Mice vaccinated with the killed Salmonella typhimurium  vaccine yielded 
a high antibody titre that was statistically significant in comparison with 
the PBS control group (P ≤0.05).  Interestingly, there was no differences 
between the vaccinated group dosed with the extract versus unvaccinated 
groups. It would appear that the antibody titre in vaccinated mice treated 
with the extract was suppressed. 
32 
       
4.2.2 Total antibody titres in vaccinated versus non-vaccinated mice 
administered Astragalus membranaceus extract by 
intraperitoneal route 
 
In this study, three groups of mice were treated with the extract of A. 
membranaceus. Two of these groups were vaccinated with killed 
Salmonella typhimurium vaccine, with one injected with sterile phosphate 
buffered saline and the other filter sterilised A. membranaceus extract. An 
un-vaccinated group was also injected with filter sterilised A. 
membranaceus extract. Serum was collected from the mice after 28 days 
and antibody titres determined by ELISA. Statistical analysis of the data is 
presented in Appendix D. Presentation of the results as a histogram is 
presented as Figure 4.3. 
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Figure 4.3 Histogram of antibody titres for intra-peritoneal injection of 
Astragalus membranaceus extract or placebo (Phosphate buffered saline). 
Legend: PBS Vac – PBS control, vaccinated. Ext Vac – Astragalus 
membranaceus extract, vaccinated, Ext – Astragalus membranaceus 
extract. 
 
The results obtained demonstrate no statistically significant difference in 
the anti-salmonella antibody titres when compared with the control group 
receiving only the extract. However, the mean antibody titre of the group 
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immunised with the killed Salmonella vaccine was substantially greater 
than of the vaccinated group injected with the extract. This indicated 
potential suppression of antibody response by A. membranaceus extract 
when administered by the intraperitoneal route. 
 
4.2.1 Determination of Interferon-γ levels in vaccinated versus non-
vaccinated mice administered Astragalus membranaceus  
extract via the oral route 
 
In addition to the determination of total antibody titre in the initial dosage 
round, determination of interferon-γ levels was conducted on stimulated 
splenocyte supernatants. Statistical analysis of the results is presented in 
Appendix D. A histogram of the obtained results is reported as Figure 
4.4. 
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Figure 4.4 Histogram of interferon-γ levels of stimulated splenocyte 
supernatants following dosage of mice orally with Astragalus 
membranaceus extract or placebo (Phosphate buffered saline) and 
vaccination with killed Salmonella typhimurium vaccine. 
 
The obtained results for this study indicate no statistically significant 
differences between the groups. The control group dosed with phosphate 
buffered saline and not vaccinated with killed Salmonella typhimurium 
vaccine has shown a marginally lower mean when compared with the 
other groups. 
 
4.2.2 Interferon-γ levels in vaccinated versus non-vaccinated mice 
administered Astragalus membranaceus extract by 
intraperitoneal route. 
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Splenocytes from the different groups of mice described in section 4.2.2 
were stimulated with the Salmonella antigen for 72 hours and 
supernatants collected. The concentrations of interferon-γ were 
determined on this collected supernatant. Analysis of this data is 
presented as a histogram in Figure 4.5. 
 
Analysis of variance of the results revealed that there was no statistically 
significant difference between the groups. It was clear that there was no 
stimulation of CMI following administration of Astragalus 
membranaceus extract by the intraperitoneal injection. 
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 Figure 4.5 Histogram for interferon-γ levels of stimulated splenocyte 
supernatants following intraperitoneal injection with Astragalus 
membranaceus extract or placebo (Phosphate buffered saline) and 
vaccination with killed Salmonella typhimurium vaccine. Ext:  
A.membranaceus extract, Ext Vac- A.membranaceus extract and 
vaccination with Salmonella typhimurium vaccine, PBS Vac- phosphate 
buffered saline with Salmonella typhimurium  vaccine. 
 
4.2.5 Determination of serum interferon-γ levels in mice administered 
Astragalus membranaceus extract by the oral route. 
 
This study, and those reported subsequent to this, were performed 
following assessment of the results of the initial studies conducted. Serum 
interferon-γ levels were assessed for mice dosed orally with A. 
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membranaceus extract. In addition, groups were dosed with three 
fractions derived from whole extract in an attempt to identify likely 
classes of compound involved in the production of any observed 
immunological response.  
 
 
 
Figure 4.6 Histogram for interferon-γ levels of serum following oral 
administration of Astragalus membranaceus extract, fractions derived 
from A. membranaceus or placebo (Phosphate buffered saline). Legend: 
Extract- A. membranaceus extract, Lipophil – Lipophilic fraction, 
Hydrophi – Hydrophilic fraction, Polysac – Polysaccharide fraction, PBS 
– phosphate buffered saline. 
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No statistically relevant differences were observed to be present between 
groups. Analysis of variance revealed no evidence to support the 
hypothesis that the Astragalus membranaceus extract, or fractions 
derived from A. membranaceus enhanced the production of interferon-γ 
in mice. 
 
4.2.3 Interferon-gamma levels in mice administed Astragalus 
membranaceus extract or fractions derived from Astragalus 
membranaceus by the oral route. 
 
Stimulated splenocyte supernatants derived from mice dosed as in 4.2.5 
were assessed for production of interferon-γ. Statistical analysis of the 
results is presented in Appendix D. The results are presented as a 
histogram in Figure 4.7. 
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 Figure 4.7 Histogram of interferon-γ levels of stimulated splenocyte 
supernatants following oral administration of Astragalus membranaceus 
extract, fractions derived from A. membranaceus or placebo (Phosphate 
buffered saline). Extract- A. membranaceus extract, Lipophil – Lipophilic 
fraction, Hydrophi – Hydrophilic fraction, Polysac – Polysaccharide 
fraction, PBS – phosphate buffered saline. 
 
Analysis of variance on the data presented as a histogram in Figure 4.7 
showed no statistically relevant differences in the levels of interferon-γ 
produced by the different groups. Hence there was no evidence to support 
the hypothesis that the extract of A. membranaceus or fractions derived 
from the extract enhanced cell mediated immunity. 
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 4.2.4 Serum Interleukin-12 levels in mice following oral 
administration of Astragalus membranaceus extract or 
fractions derived from Astragalus membranaceus. 
 
In this study serum interleukin-12 levels were assessed in mice dosed 
orally with A. membranaceus extract or with three fractions derived from 
whole extract in an attempt to identify likely classes of compound 
involved in the production of any observed immunological response. 
Statistical analysis of the results for this data is presented in Appendix D. 
A histogram representing the serum interleukin-12 levels in the different 
groups of mice is shown in Figure 4.8. 
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 Figure 4.8 Histogram for interleukin-12 levels in serum following oral 
administration of Astragalus membranaceus extract, fractions derived 
from A. membranaceus or placebo (Phosphate buffered saline). 
Legend: Extract- A. membranaceus extract, Lipophil – Lipophilic 
fraction, Hydrophi – Hydrophilic fraction, Polysac – Polysaccharide 
fraction, PBS – phosphate buffered saline. 
 
 
Analysis of variance performed on the serum interleukin-12 levels 
revealed no statistically relevant differences between the different groups. 
These results provided further evidence to support the hypothesis that the 
extract of A. membranaceus or isolated fractions did not enhance innate 
immunity in mice. 
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Chapter 5: Discussion and Conclusions 
 
The use of Astragalus membranaceus as a traditional Chinese medicine in 
a variety of applications for support of immune function is well 
documented (Anonymous , Alternative Medicine Review, 2003). The 
transition of this herb into contemporary western usage has resulted in the 
presentation of extracts, which in some cases are quite markedly different 
in methods of preparation in comparison to the presentation as a 
traditional dosage form. Although the use of cycloartane triterpene 
glycoside, Astragaloside IV is widely reported as a characteristic and 
active constituent (Li et al, 2001), standardisation of extracts to a 
recommended level of this compound, or any other of the phytochemical 
components, is not accepted as a rule or conducted.  
 
5.1 Rationale for this study 
In the studies published to date on the immunomodulatory activity of 
Astragalus membranaceus, much of the work has involved aqueous 
extracts as opposed to the ethanolic extracts utilised in the course of this 
study Current use of Astragalus in Australia is as a herbal medicine 
available as a Listed medicine. The listing process for products on the 
Australian Register of Therapeutic Goods requires evidence to be 
available supporting the quality and safety of the medicine, but no 
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assessment of the efficacy for the claimed therapeutic uses of the product. 
Safety is established by way of review of available supportive 
documentation, not by way of assessment of the claimed therapeutic 
properties of the individual products (Australian Regulatory Guidelines 
for Complementary Medicines, 2005) 
 
Products assessed using these protocols are assigned an AUST L number 
and are available over the counter for the purpose of self-medication by 
the public. These products are taken via the oral route. Many of the 
papers published to date indicating the expression of positive 
immunostimulation as a consequence of administration of extracts of 
Astragalus membranaceus were the result of administration via the 
intraperitoneal route. This approach is at odds with the general use of 
Astragalus extracts in Australia. Additionally, much of the body of work 
previously conducted relates to the use of aqueous extracts. Although no 
profile of the phytochemical constituents was prepared as a part of this 
study, it is reasonable to expect that the components present in this 
extract, which is widely available in an over the counter preparation of 
Greenridge Botanicals in Australia, are likely to be substantially different 
to that found in an aqueous extract. It was therefore of interest to 
determine the immunomodulatory potential of the ethanolic extracts of A. 
membranaceus on adaptive immunity by using an inactivated Salmonella 
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vaccine which has been demonstrated to induce only an antibody 
response but no cell mediated immunity. The potential of the A. 
membranaceus extract or fractions derived there from to stimulate innate 
immunity was also investigated. 
 
5.2.1  Antibody response 
 
Determination of the total antibody titre following administration of 
ethanolic extracts of Astragalus membranaceus to mice by either of  the 
oral or intraperitoneal routes demonstrated that there was no enhancement  
of humoral immune response. There was suppression of response instead. 
Elevation of titres in the PBS control groups vaccinated with the killed 
Salmonella typhimurium vaccine was consistent with previous studies 
(Mukkur et al, 1992). Failure to induce an antibody response during these 
initial determinations was the reason why no determination of antibody 
titres in experiments involving the use of the isolated fractions were 
carried out.  
 
Given that the extract used in the course of these investigations was 
prepared by initially macerating the root matter in 60% v/v ethanol in 
water, it is highly probable that the content of polysaccharides and other 
water soluble compounds would be markedly lower than what would be 
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expected in an aqueous extract. This is a fundamental point of difference 
between the extracts used in these studies in comparison to the majority 
of previously published data where aqueous extract preparations were 
used. Regardless, results obtained in this investigation do raise an issue 
with the use of A membranaceus as a component of “AstraForte” that is 
currently marketed as a potential immunostimulant. 
 
5.2.2 Cell-mediated immune response 
 
Results of the initial determinations of IFN-γ in splenocyte culture 
supernatants from mice, vaccinated with killed Salmonella vaccine 
previously shown to induce only an antibody response, and 
simultaneously gavaged with the extract showed no significant difference 
in the levels of this cytokine when compared with the control groups.  
In order to further explore the possibility that A. membranaceus extract 
may modulate innate immunity, further determinations were then made 
on the potential of the crude extract as well as the isolated hydrophilic, 
lipophilic and polysaccharide fractions  administered by the oral route. 
No statistically significant difference between the PBS control groups, 
crude extract or fractions derived therefrom. It therefore appeared that 
there was no evidence that a 60% v/v ethanol in water extract of 
Astragalus membranaceus modulated CMI response.  
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 5.2.3 Determination of Interleukin-12 Levels 
 
As part of the examination of the potential for the extract of Astragalus 
membranaceus to promote and/or modify the immune response, it was 
decided to investigate the potential impact of this extract on innate 
immunity as judged by induction of IL-12.  
This is significant because of the role of IL-12 in the activation and/or 
generation of Tc and NK cells (Coico et al., 2003), production of which 
of may ensure that there was no decreased production of IFN-γ, the most 
potent macrophage-activating agent in vivo (Marodi, 2006). Since there 
were no statistically significant differences in the IL-12 levels between 
the groups dosed orally with whole A. membranaceus extract or fractions 
derived versus the PBS control group, the hypothesis that the extract 
modulates CMI responses was not substantiated. 
 
5.4 Future research directions 
Given that there was potential suppression of antibody response and no 
promotion of acquired cell-mediated immunity response or innate 
immunity, potential of this herb as an immunosuppressant in autoimmune 
diseases mediated by antibodies to self-antigens warrants further 
investigation. However, prior to such trials in humans it is imperative to 
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re-evaluate the immunomodulatory properties of the aqueous preparations 
of Astragalus membranaceus which are relatively rich in polysaccharides,  
administered by the oral route, using the mouse model described in this 
investigation. 
 
5.5 Conclusions 
 
Investigation on the immunomodulatory potential of Astragalus 
membranaceus, presented in this thesis, have not supported the 
previously reported communications on the enhancement of immune 
response by extracts of Astragalus membranaceus, notwithstanding the 
fact that the extract in most investigations was administered by a systemic 
rather than the genuine oral route of administration. Analysis of the data 
on the immune parameters obtained in this investigation revealed that oral 
administration of the Astragalus membranaceus extract did not enhance 
either the antibody or cell-mediated immune response to the Salmonella 
vaccine antigens used for immunisation of mice but instead there was a 
potential suppression of the antibody response. In traditional medicine, 
this herb is not recommended for use in acute infections [Bone, 2000]. 
Given its potential immunosuppressive property, this herb clearly cannot 
be recommended as an immunostimulant.  
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If the immunomodulatory potential of Astragalus membranaceus is due 
to a polysaccharide component, as has been reported to be the case with 
Echinacea species (Wagner et al, 1985) then further experiments using 
extraction with solvents containing a lower concentration of ethanol or 
aqueous extracts will be warranted to obtain a resolution to this important 
question.   On the other hand, if the results obtained in this investigation 
are re-confirmed, then attempts to isolate the compound responsible for 
the immunosuppressant property of A membranaceus will be warranted.  
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APPENDIX A:  
 
 
Thin-Layer Chromatography 
 
A sample of 1 gram of the milled herb was extracted by boiling in 10mL 
of methanol for 30 minutes. The mixture was filtered through a Whatman 
No.4 filter paper. Preparation of the reference solution was conducted in 
the same way. 10μL of the resultant liquid was applied as a band approx 
10mm from the base of a silica C60 F264 TLC plate (Alltech). The plate 
was placed into an equilibrated tank containing acetic acid, formic acid, 
water and ethyl acetate as a solvent system in the ratio 11:11:27:100. The 
plate was allowed to run until the solvent front was approximately 9 cm 
up the plate, when it was removed and air dried. The plate was then 
sprayed with 1% w/v methanolic diphenylboric acid followed by 5% 
ethanolic polyethylene glycol and viewed under UV light at 365nm. 
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APPENDIX B: Reagents 
 
Coupling buffer:  
Na2CO3   1.18g 
NaH CO3   3.47g 
Dissolve in 1L of distilled water and adjust to pH 9.6. Store at 4°C and 
use within a fortnight. 
 
Phosphate Buffered Saline 
NaCl    8.0g 
Na2HPO4   1.1375g 
KCl    0.2g 
KH2PO4   0.2g 
 
Dissolve in 975mL of distilled water and adjust pH to 7.2 with 
phosphoric acid. Make to  a final volume of one litre and prepare fresh 
weekly. 
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Tissue Culture Media 
(i) Without fetal bovine serum (FBS) 
To Dulbecco’s modified eagle media (Gibco, Aukland NZ) add 
25mN HEPES, 12μM 2-mercaptoethanol and 100 units/mL 
penicillin-streptomycin 
 
(ii) With 10% FBS 
Add 10% fetal bovine serum to the media in (I). 
 
Wash buffer 
 
To 1L PBS add 0.5mL Tween 20 (Sigma, St. Louis). 
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APPENDIX C:  Mouse Interferon-γ Assay procedure: 
 
1. Prepare all reagents, samples and standards. 
2. Remove excess microplate strips from the plate frame. 
3. Add 50 microloitres of Assay diluent RD1-21 to each well. 
4. Add 50 microlitres of standard, control or sample to the centre of each 
well. Mix by gently tapping the plate frame for 1 minute. Cover the 
plate and incubate for 2 hours at room temperature. 
5. Aspirate and wash each well 5 times. 
6. Add 100 microlitres of mouse IFN-γ conjugate to each well. Cover 
and incubate for 2 hours at room temperature.  
7. Wash as in step 5. 
8. Add 100 microlitres of substrate solution to each well. Gently tap the 
plate to ensure thorough mixing. Incubate for 30 minutes at room 
temperature protected from light. 
9. Add 100 microlitres of stop solution to each well. Gently taps to 
ensure mixing. 
10. Determine the optical density of each well within 30 minutes using a 
microplate reader set to 450nm. 
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APPENDIX D: Raw Data and Statistical Analysis 
 
 
D.1 Total antibody titres in mice following oral gavage with Astragalus 
membranaceus 
 
 
Group Titre Group Titre 
PBS 10.7 Ext 7.1
PBS 5.4 Ext 0
PBS 1.8 Ext 0
PBS 1.9 Ext 13.1
PBS 0 Ext 6.3
PBS 1.4 Ext 17.5
PBS 1.1 PBS Vac 2.6
Ext Vac 11.7 PBS Vac 136.8
Ext Vac 0 PBS Vac 155.7
Ext Vac 8.2 PBS Vac 26.96
Ext Vac 5.3 PBS Vac 152.6
Ext Vac 13.7 PBS Vac 160.9
Ext Vac 19.3
Ext Vac 13.6
 
 
 
 
Analysis of Variance Report 
Page/Date/Time 1    15/05/2005 11:04:40 AM 
Database C:\Program Files\NCSS97\Report\total antibody.S0 
Response C2 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals -2.9689 0.002988 Reject 
Kurtosis Normality of Residuals 2.8996 0.003736 Reject 
Omnibus Normality of Residuals 17.2224 0.000182 Reject 
Modified-Levene Equal-Variance Test 3.7577 0.025587 Reject 
 
 
 
Expected Mean Squares Section 
Source  Term Denominator Expected 
Term DF Fixed? Term Mean Square 
A: C1 3 Yes S(A) S+sA 
S(A) 22 No  S(A) 
Note: Expected Mean Squares are for the balanced cell-frequency case. 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob
 Power 
Term DF Squares Square F-Ratio Level
 (Alpha=0.05) 
62 
A: C1 3 45431.78 15143.93 12.76 0.000048*
 0.998995 
S(A) 22 26111.97 1186.908 
Total (Adjusted) 25 71543.74 
Total 26 
* Term significant at alpha = 0.05 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level
 Decision(0.05) 
Not Corrected for Ties 3 11.11762 0.011107 Reject Ho 
Corrected for Ties 3 11.15576 0.010913 Reject Ho 
 
Number Sets of Ties 1 
Multiplicity Factor 60 
 
Group Detail 
  Sum of Mean 
Group Count Ranks Rank Z-Value Median 
Oral Extract vaccinated 7 100.50 14.36 0.3468 11.7 
Oral PBS non-vaccinated 6 129.00 21.50 2.9212
 144.7 
Oral PBS vaccinated 7 54.50 7.79 -2.3123 1.8 
Oral extract non-vaccinated 6 67.00 11.17 -0.8520 6.7 
 
Means and Effects Section 
   Standard  
Term Count Mean Error Effect 
All 26 29.75615 
 31.67571 
A: C1 
Oral Extract vaccinated 7 10.25714 13.02145 -
21.41857 
Oral PBS non-vaccinated 6 105.9267 14.06478
 74.25095 
Oral PBS vaccinated 7 3.185714 13.02145 -28.49 
Oral extract non-vaccinated 6 7.333333 14.06478 -
24.34238 
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D.2 Total antibody titres in vaccinated versus non-vaccinated mice 
administered Astragalus membranaceus extract by intraperitoneal route 
 
Group Titre 
PBS Vac 157.8 
PBS Vac 153.4 
PBS Vac 18.2 
PBS Vac 18.2 
PBS Vac 17 
PBS Vac 14.1 
PBS Vac 21.9 
PBS Vac 24.8 
Ext Vac 21.9 
Ext Vac 21.5 
Ext Vac 12.6 
Ext Vac 8.8 
Ext Vac 15.4 
Ext Vac 14.9 
Ext Vac 15.5 
Ext Vac 14.8 
Ext 15.6 
Ext 13 
Ext 4.5 
Ext 3.4 
Ext 0 
Ext 8 
Ext 19.6 
 
Analysis of Variance Report 
Page/Date/Time 1    15/05/2005 11:15:36 AM 
Database C:\Program Files\NCSS97\Report\Total antibody IP.S0 
Response C2 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals 3.5393 0.000401 Reject 
Kurtosis Normality of Residuals 2.8289 0.004670 Reject 
Omnibus Normality of Residuals 20.5296 0.000035 Reject 
Modified-Levene Equal-Variance Test 2.0405 0.156159 Accept 
 
 
 
 
 
Expected Mean Squares Section 
Source  Term Denominator Expected 
Term DF Fixed? Term Mean Square 
A: C1 2 Yes S(A) S+sA 
S(A) 20 No  S(A) 
Note: Expected Mean Squares are for the balanced cell-frequency case. 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob
 Power 
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Term DF Squares Square F-Ratio Level
 (Alpha=0.05) 
A: C1 2 8734.045 4367.022 3.07 0.068991
 0.526197 
S(A) 20 28492.93 1424.646 
Total (Adjusted) 22 37226.97 
Total 23 
* Term significant at alpha = 0.05 
 
 Analysis of Variance Report 
Page/Date/Time 2    15/05/2005 11:15:36 AM 
Database C:\Program Files\NCSS97\Report\Total antibody IP.S0 
Response C2 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level
 Decision(0.05) 
Not Corrected for Ties 2 9.242042 0.009843 Reject Ho 
Corrected for Ties 2 9.251184 0.009798 Reject Ho 
 
Number Sets of Ties 2 
Multiplicity Factor 12 
 
Group Detail 
  Sum of Mean 
Group Count Ranks Rank Z-Value Median 
IP Extract non-vaccinated 8 138.50 17.31 2.7434
 20.05 
IP Extract vaccinated 8 90.50 11.31 -0.3550 15.15 
IP PBS vaccinated 7 47.00 6.71 -2.4722 8 
 
Means and Effects Section 
   Standard  
Term Count Mean Error Effect 
All 23 26.73478 
 26.00238 
A: C1 
IP Extract non-vaccinated 8 53.175 13.34469
 27.17262 
IP Extract vaccinated 8 15.675 13.34469 -
10.32738 
IP PBS vaccinated 7 9.157143 14.26608 -
16.84524 
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D.3 Determination of Interferon-γ levels in vaccinated versus non-
vaccinated mice administered Astragalus membranaceus extract via the 
oral route. 
 
Group Concentration 
PBS Vac 151 
PBS Vac 386 
PBS Vac 279 
PBS Vac 231 
PBS Vac 138 
PBS Vac 222 
PBS Vac 397 
PBS Vac 409 
Ext Vac 69 
Ext Vac 228 
Ext Vac 365 
Ext Vac 409 
Ext Vac 409 
Ext Vac 409 
Ext Vac 373 
Ext Vac 395 
Ext Vac 396 
Ext 135 
Ext 310 
Ext 376 
Ext 400 
Ext 328 
Ext 275 
Ext 336 
Ext 96 
Ext 222 
PBS 19 
PBS 83 
PBS 136 
PBS 69 
PBS 46 
PBS 13 
PBS 44 
PBS 93 
PBS 29 
 
 
 
Analysis of Variance Report 
Page/Date/Time 1    15/05/2005 10:17:45 AM 
Database  
Response C2 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
66 
Skewness Normality of Residuals -2.4449 0.014491 Reject 
Kurtosis Normality of Residuals 1.4562 0.145325 Accept 
Omnibus Normality of Residuals 8.0980 0.017440 Reject 
Modified-Levene Equal-Variance Test 2.5830 0.071113 Accept 
 
 
 
Expected Mean Squares Section 
Source  Term Denominator Expected 
Term DF Fixed? Term Mean Square 
A: C1 3 Yes S(A) S+sA 
S(A) 31 No  S(A) 
Note: Expected Mean Squares are for the balanced cell-frequency case. 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob
 Power 
Term DF Squares Square F-Ratio Level
 (Alpha=0.05) 
A: C1 3 43.47584 14.49195 21.90 0.000000*
 1.000000 
S(A) 31 20.51796 0.6618698 
Total (Adjusted) 34 63.9938 
Total 35 
* Term significant at alpha = 0.05 
 
Analysis of Variance Report 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level
 Decision(0.05) 
Not Corrected for Ties 3 21.12553 0.000099 Reject Ho 
Corrected for Ties 3 21.15812 0.000098 Reject Ho 
 
Number Sets of Ties 2 
Multiplicity Factor 66 
 
Group Detail 
  Sum of Mean 
Group Count Ranks Rank Z-Value Median 
Control - vaccinated 8 171.00 21.38 1.0607 2.186 
Extract - non vaccinated 9 180.50 20.06 0.6982 2.649 
Extract - vaccinated 9 233.50 25.94 2.6986 3.383 
PBS Control - non vaccinated 9 45.00 5.00 -4.4159
 0.039 
 
Means and Effects Section 
   Standard  
Term Count Mean Error Effect 
All 35 1.906857 
 1.919681 
A: C1 
Control - vaccinated 8 2.3685 0.2876347
 0.4488195 
67 
Extract - non vaccinated 9 2.356 0.2711846
 0.4363194 
Extract - vaccinated 9 2.903667 0.2711846
 0.9839861 
PBS Control - non vaccinated 9 5.055556E-02 0.2711846 -
1.869125 
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D.4 Interferon-γ levels in vaccinated versus non-vaccinated mice 
administered Astragalus membranaceus extract by intraperitoneal route. 
 
Group Concentration 
Ext 0 
Ext 8 
Ext 11 
Ext 8 
Ext 0 
Ext 14 
Ext 27 
Ext 33 
Ext 47 
Ext Vac 41 
Ext Vac 12 
Ext Vac 30 
Ext Vac 16 
Ext Vac 7 
Ext Vac 0 
Ext Vac 34 
Ext Vac 6 
Ext Vac 23 
PBS Vac 5 
PBS Vac 5 
PBS Vac 7 
PBS Vac 25 
PBS Vac 12 
PBS Vac 9 
PBS Vac 40 
PBS Vac 40 
PBS Vac 14 
 
Analysis of Variance Report 
Page/Date/Time 1    15/05/2005 10:27:50 AM 
Database C:\Program Files\NCSS97\Report\total antibody.S0 
Response C2 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals 1.4379 0.150458 Accept 
Kurtosis Normality of Residuals -1.3393 0.180462 Accept 
Omnibus Normality of Residuals 3.8614 0.145045 Accept 
Modified-Levene Equal-Variance Test 0.0271 0.973339 Accept 
 
 
 
Expected Mean Squares Section 
Source  Term Denominator Expected 
Term DF Fixed? Term Mean Square 
A: C1 2 Yes S(A) S+sA 
S(A) 21 No  S(A) 
Note: Expected Mean Squares are for the balanced cell-frequency case. 
 
Analysis of Variance Table 
69 
Source  Sum of Mean  Prob
 Power 
Term DF Squares Square F-Ratio Level
 (Alpha=0.05) 
A: C1 2 6.090278E-05 3.045139E-05 0.21 0.809891
 0.078940 
S(A) 21 3.002431E-03 1.429729E-04 
Total (Adjusted) 23 3.063333E-03 
Total 24 
* Term significant at alpha = 0.05 
 
Analysis of Variance Report 
 
Page/Date/Time 2    15/05/2005 10:27:50 AM 
Database C:\Program Files\NCSS97\Report\total antibody.S0 
Response C2 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level
 Decision(0.05) 
Not Corrected for Ties 2 0.8 0.670320 Accept Ho 
Corrected for Ties 2 0.8020924 0.669619 Accept Ho 
 
Number Sets of Ties 6 
Multiplicity Factor 36 
 
Group Detail 
  Sum of Mean 
Group Count Ranks Rank Z-Value Median 
IP Extract - non vaccinated 7 94.50 13.50 0.4446
 0.012 
IP PBS vaccinated 9 97.50 10.83 -0.8944 0.01 
IP extract vaccinated 8 108.00 13.50 0.4899 0.017 
 
Means and Effects Section 
   Standard  
Term Count Mean Error Effect 
All 24 1.683333E-02 
 1.696759E-02 
A: C1 
IP Extract - non vaccinated 7 0.018 4.519369E-03
 1.032407E-03 
IP PBS vaccinated 9 1.477778E-02 3.985709E-03 -
2.189815E-03 
IP extract vaccinated 8 0.018125 4.227483E-03
 1.157407E-03 
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D.5 Determination of serum interferon-γ levels in mice administered 
Astragalus membranaceus extract by the oral route. 
 
 
Group Concentration 
Extract 30 
Extract 235 
Extract 47 
Extract 10 
Extract 10 
Extract 38 
Extract 24 
Extract 29 
Lipophil 18 
Lipophil 19 
Lipophil 21 
Lipophil 154 
Lipophil 18 
Lipophil 21 
Lipophil 141 
Lipophil 125 
Hydrophi 114 
Hydrophi 43 
Hydrophi 20 
Hydrophi 104 
Hydrophi 20 
Hydrophi 53 
Hydrophi 136 
Hydrophi 137 
Polysac 140 
Polysac 124 
Polysac 159 
Polysac 131 
Polysac 135 
Polysac 34 
Polysac 150 
Polysac 18 
PBS 21 
PBS 112 
PBS 136 
PBS 212 
PBS 106 
PBS 117 
PBS 159 
PBS 73 
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Analysis of Variance Report 
Page/Date/Time 1    15/05/2005 11:34:06 AM 
Database C:\Program Files\NCSS97\Report\IFN-g serum rd2.S0 
Response C3 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals 2.3227 0.020197 Reject 
Kurtosis Normality of Residuals 1.7880 0.073783 Accept 
Omnibus Normality of Residuals 8.5916 0.013626 Reject 
Modified-Levene Equal-Variance Test 0.1659 0.954282 Accept 
 
 
Expected Mean Squares Section 
Source  Term Denominator Expected 
Term DF Fixed? Term Mean Square 
A: C1 4 Yes S(A) S+sA 
S(A) 35 No  S(A) 
Note: Expected Mean Squares are for the balanced cell-frequency case. 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob
 Power 
Term DF Squares Square F-Ratio Level
 (Alpha=0.05) 
A: C1 4 0.7172086 0.1793022 0.97 0.436429
 0.274307 
S(A) 35 6.471808 0.1849088 
Total (Adjusted) 39 7.189017 
Total 40 
* Term significant at alpha = 0.05 
 
Analysis of Variance Report 
Page/Date/Time 2    15/05/2005 11:34:06 AM 
Database C:\Program Files\NCSS97\Report\IFN-g serum rd2.S0 
Response C3 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level
 Decision(0.05) 
Not Corrected for Ties 4 4.916616 0.295961 Accept Ho 
Corrected for Ties 4 4.918 0.295815 Accept Ho 
 
Number Sets of Ties 3 
Multiplicity Factor 18 
 
Group Detail 
  Sum of Mean 
Group Count Ranks Rank Z-Value Median 
Crude extract 8 118.50 14.81 -1.5385 0.14 
72 
Extract - Lipophilic fraction 8 203.00 25.38 1.3187
 0.889 
Extract - hydrophilic fraction 8 148.00 18.50 -0.5410
 0.525 
Extract - polysaccharide fraction 8 200.50 25.06 1.2342
 0.7675 
PBS control 8 150.00 18.75 -0.4734 0.293 
 
Means and Effects Section 
   Standard  
Term Count Mean Error Effect 
All 40 0.61085  0.61085 
A: C1 
Crude extract 8 0.432125 0.1520316 -
0.178725 
Extract - Lipophilic fraction 8 0.745625 0.1520316
 0.134775 
Extract - hydrophilic fraction 8 0.5245 0.1520316 -
0.08635 
Extract - polysaccharide fraction 8 0.784625 0.1520316
 0.173775 
PBS control 8 0.567375 0.1520316 -
0.043475 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
73 
 
D.6 Interferon-γ levels in mice administered Astragalus membranaceus 
extract or fractions derived from Astragalus membranaceus by the oral 
route 
 
Group Concentration 
Extract 109 
Extract 119 
Extract 16 
Extract 21 
Extract 153 
Extract 123 
Extract 118 
Extract 138 
Extract 116 
Lipophil 187 
Lipophil 23 
Lipophil 96 
Lipophil 145 
Lipophil 85 
Lipophil 33 
Hydrophi 195 
Hydrophi 119 
Hydrophi 99 
Hydrophi 12 
Hydrophi 167 
Hydrophi 156 
Hydrophi 41 
Hydrophi 21 
Hydrophi 22 
Polysac 11 
Polysac 13 
Polysac 141 
Polysac 132 
Polysac 144 
Polysac 139 
Polysac 74 
Polysac 12 
Polysac 40 
PBS 24 
PBS 21 
PBS 26 
PBS 19 
PBS 52 
PBS 147 
PBS 53 
PBS 24 
PBS 127 
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Analysis of Variance Report 
Page/Date/Time 1    15/05/2005 11:41:55 AM 
Database C:\Program Files\NCSS97\Report\IFN-g serum rd2.S0 
Response C4 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals 0.3059 0.759708 Accept 
Kurtosis Normality of Residuals -2.9073 0.003646 Reject 
Omnibus Normality of Residuals 8.5458 0.013941 Reject 
Modified-Levene Equal-Variance Test 1.1698 0.339873 Accept 
 
 
 
Expected Mean Squares Section 
Source  Term Denominator Expected 
Term DF Fixed? Term Mean Square 
A: C1 4 Yes S(A) S+sA 
S(A) 37 No  S(A) 
Note: Expected Mean Squares are for the balanced cell-frequency case. 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob
 Power 
Term DF Squares Square F-Ratio Level
 (Alpha=0.05) 
A: C1 4 0.5401716 0.1350429 0.87 0.489229
 0.250405 
S(A) 37 5.722229 0.1546548 
Total (Adjusted) 41 6.262401 
Total 42 
* Term significant at alpha = 0.05 
 
Analysis of Variance Report 
Page/Date/Time 2    15/05/2005 11:41:55 AM 
Database C:\Program Files\NCSS97\Report\IFN-g serum rd2.S0 
Response C4 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level
 Decision(0.05) 
Not Corrected for Ties 4 2.034699 0.729377 Accept Ho 
Corrected for Ties 4 2.034864 0.729346 Accept Ho 
 
Number Sets of Ties 1 
Multiplicity Factor 6 
 
Group Detail 
  Sum of Mean 
Group Count Ranks Rank Z-Value Median 
Crude Extract 6 146.00 24.33 0.6111 0.6085 
75 
Extract - hydrophilic fraction 9 209.00 23.22 0.4751
 0.665 
Extract - lipophilic fraction 9 177.00 19.67 -0.5058
 0.499 
Extract - polysaccharide fraction 9 156.50 17.39 -1.1342
 0.171 
PBS control 9 214.50 23.83 0.6437 0.79 
 
Means and Effects Section 
   Standard  
Term Count Mean Error Effect 
All 42 0.5604762 
 0.5654333 
A: C1 
Crude Extract 6 0.6348333 0.1605484 0.0694 
Extract - hydrophilic fraction 9 0.6191111 0.1310873
 5.367778E-02 
Extract - lipophilic fraction 9 0.5266666 0.1310873 -
3.876667E-02 
Extract - polysaccharide fraction 9 0.3667778 0.1310873 -
0.1986556 
PBS control 9 0.6797778 0.1310873
 0.1143444 
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D.7 Serum Interleukin-12 levels in mice following oral administration of 
Astragalus membranaceus extract or fractions derived from Astragalus 
membranaceus. 
 
Group Concentration 
Extract 6646 
Extract 6581 
Extract 2127 
Extract 4204 
Extract 4447 
Extract 2081 
Extract 3722 
Extract 3784 
Lipophil 1680 
Lipophil 2810 
Lipophil 2799 
Lipophil 6359 
Lipophil 3452 
Lipophil 2001 
Lipophil 5187 
Lipophil 3984 
Hydrophi 1709 
Hydrophi 3824 
Hydrophi 3932 
Hydrophi 2254 
Hydrophi 2945 
Hydrophi 3078 
Hydrophi 3211 
Hydrophi 3344 
Polysac 3477 
Polysac 3610 
Polysac 3743 
Polysac 3876 
Polysac 3141 
Polysac 3344 
Polysac 1849 
Polysac 2561 
PBS 1500 
PBS 3657 
PBS 2185 
PBS 2157 
PBS 4137 
PBS 3304 
PBS 2237 
PBS 2964 
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Analysis of Variance Report 
Page/Date/Time 1    15/05/2005 1:35:22 PM 
Database C:\Program Files\NCSS97\Report\IFN-g serum rd2.S0 
Response C5 
 
Tests of Assumptions Section 
 Test Prob Decision 
Assumption Value Level (0.05) 
Skewness Normality of Residuals 1.2810 0.200194 Accept 
Kurtosis Normality of Residuals 0.2719 0.785664 Accept 
Omnibus Normality of Residuals 1.7149 0.424239 Accept 
Modified-Levene Equal-Variance Test 1.2082 0.324758 Accept 
 
 
 
Expected Mean Squares Section 
Source  Term Denominator Expected 
Term DF Fixed? Term Mean Square 
A: C1 4 Yes S(A) S+sA 
S(A) 35 No  S(A) 
Note: Expected Mean Squares are for the balanced cell-frequency case. 
 
Analysis of Variance Table 
Source  Sum of Mean  Prob
 Power 
Term DF Squares Square F-Ratio Level
 (Alpha=0.05) 
A: C1 4 3.204224 0.8010559 1.84 0.143082
 0.501807 
S(A) 35 15.23278 0.4352223 
Total (Adjusted) 39 18.437 
Total 40 
* Term significant at alpha = 0.05 
 
Analysis of Variance Report 
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Response C5 
 
Kruskal-Wallis One-Way ANOVA on Ranks 
Hypotheses 
Ho: All medians are equal. 
Ha: At least two medians are different. 
 
Test Results 
  Chi-Square Prob 
Method DF (H) Level
 Decision(0.05) 
Not Corrected for Ties 4 4.207317 0.378675 Accept Ho 
Corrected for Ties 4 4.207317 0.378675 Accept Ho 
 
Number Sets of Ties 0 
Multiplicity Factor 0 
 
Group Detail 
  Sum of Mean 
Group Count Ranks Rank Z-Value Median 
Crude Extract 8 171.00 21.38 0.2367 1.649 
78 
Extract - hydrophilic fraction 8 163.00 20.38 -0.0338
 1.586 
Extract - lipophilic fraction 8 135.00 16.88 -0.9806
 1.469 
Extract - polysaccharide fraction 8 134.00 16.75 -1.0144
 1.3695 
PBS Control 8 217.00 27.13 1.7921 2.1035 
 
Means and Effects Section 
   Standard  
Term Count Mean Error Effect 
All 40 1.723925 
 1.723925 
A: C1 
Crude Extract 8 1.86125 0.233244
 0.137325 
Extract - hydrophilic fraction 8 1.611375 0.233244 -
0.11255 
Extract - lipophilic fraction 8 1.478 0.233244 -
0.245925 
Extract - polysaccharide fraction 8 1.457625 0.233244 -0.2663 
PBS Control 8 2.211375 0.233244 0.48745 
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